⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861177 | 0.79 | — | — | |
| SCHEMBL17244089 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL4574641 | 0.77 | BLM (0.32) | — | |
| SCHEMBL10161215 | 0.74 | FFAR1 (0.32) | — | |
| SCHEMBL28210060 | 0.74 | ALDH1A1 (0.31) | — | |
| SCHEMBL18058933 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL6246468 | 0.71 | — | — | |
| SCHEMBL6216099 | 0.69 | ADORA2B (0.33) | — | |
| SCHEMBL27697996 | 0.69 | CA12 (0.38) | — | |
| SCHEMBL27880331 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3890737-B1 | USP19 INHIBITORS FOR USE IN A METHOD OF TREATING OBESITY, INSULIN RESISTANCE AND TYPE II DIABETES | ALMAC DISCOVERY LTD (GB) | 2024-06-05 | — | — | EP | claimed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | claimed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-4363419-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117720516-A | Advantageous crystalline forms of selective BRD9 degrading agents | C4医药公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024002379-A1 | COMPOUND USED AS WDR5 INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE OF COMPOUND | 甘李药业股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023237015-A1 | N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | 杭州壹瑞医药科技有限公司 | 2023-12-14 | — | — | WO | disclosed |
| EP-2364973-A1 | Heterocyclic inhibitors of MEK and Methods of use thereof | Array Biopharma, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2155683-A2 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | Astellas Pharma Inc. (JP) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140066-A2 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| CN-1905873-A | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2007-01-31 | — | — | CN | disclosed |
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |